Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.00
9% from low
Exchange
OTC Link
CS
Borrow rate
13.31%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $5.2K | $8.0K | $2.7K | $999 | $0 |
| Cost of revenue | $0 | $0 | $0 | $4.3K | $214 | $1.4K | $1.2K | $549 |
| Gross profit | $0 | $0 | $0 | $943 | $7.8K | $1.3K | −$207 | −$549 |
| Gross margin | — | — | — | 18.0% | 97.3% | 48.4% | -20.7% | — |
| R&D | $0 | $0 | $20.0K | $688.5K | $913.4K | $295.9K | $67.3K | $6.0K |
| Operating income | −$14.2K | −$21.9K | −$1.6M | −$855.7K | −$1.6M | −$447.2K | −$75.0K | −$18.7K |
| EBITDA | −$14.2K | −$21.9K | $7.8K | $84.7K | −$1.6M | −$446.2K | −$74.3K | −$18.1K |
| Net income | −$14.2K | −$21.9K | −$1.6M | −$861.5K | −$1.6M | −$454.1K | −$79.7K | −$20.1K |
| Net margin | — | — | — | -16447.8% | -20258.7% | -16663.2% | -7975.6% | — |
| EPS (diluted) | -0.00 | -0.00 | -0.01 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
Annual figures · source: Financial Modeling Prep
HALBERD CORP
No one on the platform currently holds HALB.
No tracked institution reports a position in HALB as of their last filing.
No one on the platform has traded HALB yet.
| $402227 |
| — |
| ISCOInternational Stem Cell Corporation | $0.18 | +0.00% | $1M | — |
| LVCELiveCare, Inc. | $0.01 | +0.00% | $357224 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at NaN× sales vs its 1501.8× historical median P/S.
Fair value ≈ $0.00 · price $0.00 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.